clofazimine has been researched along with lenalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bonsmann, G; Kuhn, A; Ruland, V | 1 |
1 review(s) available for clofazimine and lenalidomide
| Article | Year |
|---|---|
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Clofazimine; Cyclophosphamide; Cyclosporine; Dapsone; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Isoxazoles; Leflunomide; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Rituximab; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
1 other study(ies) available for clofazimine and lenalidomide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |